Highbridge Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Highbridge Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-25,000	Closed	-$598K	–	1442
2018 Q1	$598K	Buy	+25,000	New	+$788K	0.01%	641
2016 Q4	–	Sell	-10,683	Closed	-$176K	–	1705
2016 Q3	$176K	Sell	10,683 -2,886	-21%	-$43.9K	﹤0.01%	1202
2016 Q2	$205K	Buy	+13,569	New	+$224K	﹤0.01%	1225
2016 Q1	–	Sell	-16,375	Closed	-$464K	–	1913
2015 Q4	$464K	Buy	+16,375	New	+$276K	0.01%	1026
2015 Q3	–	Sell	-14,157	Closed	-$371K	–	1903
2015 Q2	$371K	Buy	+14,157	New	+$275K	﹤0.01%	1070

Other funds holding ADMS

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Highbridge Capital Management's ADMS Position: Q2 2018 in Review

Highbridge Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q2 2018, closing a stake of 25,000 shares — an estimated $598K sold.

Highbridge Capital Management first reported a position in ADMS in Q2 2015 and held it in 5 quarters. The position peaked at $598K in Q1 2018. 126 funds tracked by Wall St. Rank hold ADMS as of Q2 2018.

Highbridge Capital Management reported no remaining Adamas Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 25,000 Adamas Pharmaceuticals shares in Q2 2018, an estimated $598K.
Highbridge Capital Management first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Highbridge Capital Management's Adamas Pharmaceuticals position peaked at $598K in Q1 2018.
126 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.